Innovision Limited Reports No Deviation in IPO Fund Utilization for FY26 Under Regulation 32
Innovision Limited has confirmed no deviation in the utilization of IPO funds raised on 23rd March 2026, with gross proceeds of 2,550 Million and net proceeds of 2097.99 Million. Of the three stated objects, repayment of borrowings amounting to 510.00 Million has been fully utilized, while working capital requirements of 1,190.00 Million and general corporate purposes of 397.99 Million remain undeployed. CRISIL Ratings Limited serves as the monitoring agency, and the filing was submitted under Regulation 32 for the year ended 31st March 2026.

*this image is generated using AI for illustrative purposes only.
Innovision Limited has filed its Statement of Deviation/Variation in utilization of funds raised through its Initial Public Offer (IPO) under Regulation 32, for the year ended 31st March 2026. The filing, submitted on 13th May 2026, confirms that no deviation or variation has occurred in the utilization of funds raised through the public issue.
IPO Fund Raising Overview
The company completed its Initial Public Offer on 23rd March 2026, raising gross proceeds of 2,550 Million from the fresh issue. Net proceeds from the offering stood at 2097.99 Million. CRISIL Ratings Limited has been appointed as the monitoring agency to oversee the utilization of these funds.
The key details of the fund-raising exercise are summarized below:
| Parameter: | Details |
|---|---|
| Mode of Fund Raising: | Initial Public Offer |
| Date of Raising Funds: | 23rd March 2026 |
| Gross Proceeds (Fresh Issue): | 2,550 Million |
| Net Proceeds: | 2097.99 Million |
| Report Filed for Year Ended: | 31st March 2026 |
| Monitoring Agency: | CRISIL Ratings Limited |
| Deviation/Variation in Use of Funds: | No |
Fund Utilization Against Original Objects
The company disclosed the utilization of IPO proceeds across three stated objects. As of the reporting period, funds have been fully deployed towards debt repayment, while working capital requirements and general corporate purposes remain pending utilization. The detailed breakdown is presented below:
| Original Object: | Original Allocation | Fund Utilised | Deviation/Variation |
|---|---|---|---|
| Repayment or prepayment of borrowings: | 510.00 Million | 510.00 Million | N.A. |
| Funding Working Capital Requirements: | 1,190.00 Million | 0 | N.A. |
| General Corporate Purposes: | 397.99 Million | 0* | N.A. |
*Note: During the reported period, an amount of ₹118/- was utilized towards bank charges incurred in the Monitoring Agency account of the company maintained with Kotak Bank Limited.
Compliance and Regulatory Context
The filing confirms that there is no deviation or variation in the objects or purposes for which the funds were raised, no deviation in the amount of funds actually utilized as against what was originally disclosed, and no change in terms of any contract referred to in the fund-raising documents. The Audit Committee's comments and auditor remarks are not applicable, as no deviation has been reported.
The statement has been digitally signed and submitted by Jyoti Sachdeva, Company Secretary and Compliance Officer (M. No. A22176), on behalf of Innovision Limited.
When does Innovision Limited plan to deploy the remaining ₹1,587.99 Million allocated for working capital requirements and general corporate purposes, and what milestones will trigger this utilization?
How might the delay in deploying working capital funds impact Innovision Limited's operational growth and competitive positioning in the near term?
Will CRISIL Ratings Limited's ongoing monitoring of fund utilization influence Innovision Limited's credit rating or future borrowing costs as the remaining IPO proceeds are deployed?

































